Skip to main content

Advertisement

Table 1 Mean (SD) [range] administered activity, length of stay in hospital, percentage 177Lu and activity retention at discharge for outpatient and inpatient administrations

From: Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

  Number of administrations Number of patients Administered activity (MBq) Time T0TD (h) 177Lu retention (%) Retained activity (MBq)
Inpatients 32 16 7079 (419) [5925–7890] 18.1 (1.5) [16.2–21.2] 36 (15) [15–62] 2537 (1079) [1087–4482]
177Lu-DOTATATE Mallinckrodt
Inpatients 24 18 7545 (204) [7076–7913] 18.2 (1.1) [16.7–21.0] 24 (7) [13–37] 1806 (494) [984–2740]
 Lutathera® AAA
Outpatients 20 15 7608 (242) [7259–8038] 5.2 (0.7) [3.6–6.3] 38 (8) [28–58] 2897 (663) [2103–4670]
 Lutathera® AAA